Robbins LLP Calls for UNCY Stockholders to Join Class Action for Shareholder Rights

Robbins LLP Urges UNCY Stockholders to Act

The law firm Robbins LLP has come forward to encourage investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) who incurred significant losses to reach out for further information regarding a class action lawsuit. This class action focuses on those investors who purchased stocks from December 29, 2025, to June 29, 2026.

Explanation of the Class Action

Unicycive Therapeutics, a clinical-stage biotechnology company, aims to create and introduce treatments targeting kidney diseases. However, the complaint filed against the company highlights serious procedural oversights, specifically regarding their third-party vendor's manufacturing practices. According to the allegations, Unicycive failed to perform adequate inspections to ensure compliance with U.S. Food and Drug Administration (FDA) standards, allowing operations to continue despite prior noted deficiencies.

The complaint underscores that during this critical period, Unicycive had submitted a New Drug Application (NDA) for its kidney disease treatment, oxylanthanum carbonate (OLC), in September 2024. Following the FDA’s acceptance of the NDA in November 2024, the situation took a downward turn. A Complete Response Letter (CRL) issued in June 2025 pointed out unresolved issues at the vendor’s facility. Stakeholders were later informed that despite a meeting with the FDA to address these deficiencies, the company did not properly audit its vendor's manufacturing practices, a critical lapse that investors were reportedly unaware of.

Investors are encouraged to recognize that they may hold valid claims under federal securities law due to the omission of these vital inspections and disclosures.

Consequences of the Allegations

On June 30, 2026, Unicycive's stock witnessed a steep decline, plummeting by 39.1% to close at $4.69 per share. This drop came alarmingly close to the market's opening, following news regarding the FDA’s CRL citing the same concerns previously raised about third-party manufacturing deficiencies. As a result, the stock's plummet has left many investors seeking legal recourse.

Who Can Participate in the Class Action?

The class action targets investors who purchased or acquired Unicycive securities between the specified dates. Those who've experienced losses may have the right to partake in legal proceedings aimed at regaining their investments. Notably, participation as a lead plaintiff is not required for those looking to benefit from potential settlements, allowing greater flexibility for investors.

Additionally, it's essential to note that Robbins LLP represents its clients on a contingency fee basis, meaning that up-front costs are not an obstacle for potential participants in this important litigation.

Robbins LLP—A Trusted Ally in Shareholder Actions

Robbins LLP is recognized as a leader in shareholder rights litigation. The firm has successfully assisted investors in recovering over $2 billion in value, proving their mettle in the often complex landscape of securities fraud and shareholder derivative litigation. Brian J. Robbins, the firm's founding partner, emphasizes the responsibility corporations possess to provide complete and accurate information to investors, ensuring the market’s integrity and fairness.

How to Get Involved

For those affected, time is of the essence. Interested investors should reach out to Robbins LLP before the critical deadline for lead plaintiffs on November 2, 2026. In doing so, they can protect their interests while contributing to a collective effort aiming for justice in this class action.

For more details about the Unicycive Therapeutics, Inc. class action, investors can contact Robbins LLP directly via phone or email.

In conclusion, with significant stakes at play, those who have faced losses in Unicycive’s stock are encouraged to act promptly and seek guidance from Robbins LLP to navigate this litigation landscape effectively.